2022
DOI: 10.3389/fphar.2022.1003241
|View full text |Cite
|
Sign up to set email alerts
|

Editorial: Herbal medicines in women’s lives

Abstract: Editorial on the Research Topic Herbal medicines in women's livesIn many areas, natural products are traditionally used to improve body conditions in several periods of a women's life, including adolescent, reproductive, and menopausal periods. In the adolescent period, medical herbs are used to enhance growth. At childbearing age, medical herbs are used to treat menstruation problems, decrease vaginal infection, and increase fertility. During pregnancy, medical herbs are used to reduce discomfort and prevent … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 14 publications
0
1
0
Order By: Relevance
“…[21,22] Studies have revealed that silibinin, with biological effects including anti-oxidation, anti-fibrosis, and anti-inflammation, holds promise for treating various liver ailments, particularly liver fibrosis, cirrhosis, and liver cancer. [23][24][25] Furthermore, sorafenib, an inhibitor targeting platelet-derived growth factor and vascular endothelial growth factor, effectively hampers both the proliferation and activation of HSCs. [26,27] Therefore, combining the therapeutic properties of silibinin and sorafenib presents a highly feasible approach to reversing the effects of liver fibrosis; However, the efficacy of silibinin and sorafenib is limited due to poor water solubility, low bioavailability, and short circulation half-life.…”
Section: Introductionmentioning
confidence: 99%
“…[21,22] Studies have revealed that silibinin, with biological effects including anti-oxidation, anti-fibrosis, and anti-inflammation, holds promise for treating various liver ailments, particularly liver fibrosis, cirrhosis, and liver cancer. [23][24][25] Furthermore, sorafenib, an inhibitor targeting platelet-derived growth factor and vascular endothelial growth factor, effectively hampers both the proliferation and activation of HSCs. [26,27] Therefore, combining the therapeutic properties of silibinin and sorafenib presents a highly feasible approach to reversing the effects of liver fibrosis; However, the efficacy of silibinin and sorafenib is limited due to poor water solubility, low bioavailability, and short circulation half-life.…”
Section: Introductionmentioning
confidence: 99%